Conditional power of antidepressant network meta-analysis
Author:
Open Access
- 5 March 2021
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 21 (1) , 1-12
Abstract
Background Conditional power of network meta-analysis (NMA) can support the planning of randomized controlled trials (RCTs) assessing medical interventions. Conditional power is the probability that updating existing inconclusive evidence in NMA with additional trial(s) will result in conclusive evidence, given assumptions regarding trial design, anticipated effect sizes, or event probabilities. Methods The present work aimed to estimate conditional power for potential future trials on antidepressant treatments. Existing evidence was based on a published network of 502 RCTs conducted between 1979-2018 assessing acute antidepressant treatment in major depressive disorder (MDD). Primary outcomes were efficacy in terms of the symptom change on the Hamilton Depression Scale (HAMD) and tolerability in terms of the dropout rate due to adverse events. The network compares 21 antidepressants consisting of 231 relative treatment comparisons, 164 (efficacy) and 127 (tolerability) of which are currently assumed to have inconclusive evidence. Results Required sample sizes to achieve new conclusive evidence with at least 80% conditional power were estimated to range between N = 894 - 4190 (efficacy) and N = 521 - 1246 (tolerability). Otherwise, sample sizes ranging between N = 49 - 485 (efficacy) and N = 40 - 320 (tolerability) may require stopping for futility based on a boundary at 20% conditional power. Optimizing trial designs by considering multiple trials that contribute both direct and indirect evidence, anticipating alternative effect sizes or alternative event probabilities, may increase conditional power but required sample sizes remain high. Antidepressants having the greatest conditional power associated with smallest required sample sizes were identified as those on which current evidence is low, i.e., clomipramine, levomilnacipran, milnacipran, nefazodone, and vilazodone, with respect to both outcomes. Conclusions The present results suggest that conditional power to achieve new conclusive evidence in ongoing or future trials on antidepressant treatments is low. Limiting the use of the presented conditional power analysis are primarily due to the estimated large sample sizes which would be required in future trials as well as due to the well-known small effect sizes in antidepressant treatments. These findings may inform researchers and decision-makers regarding the clinical relevance and justification of research in ongoing or future antidepressant RCTs in MDD.Keywords
This publication has 46 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*International Journal of Neuropsychopharmacology, 2012
- Planning future studies based on the conditional power of a meta‐analysisStatistics in Medicine, 2012
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2010
- Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorderMenopause, 2010
- A Randomized, Double-Blind, Placebo-Controlled Trial of Desvenlafaxine Succinate in Adult Outpatients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2007
- The cost of dichotomising continuous variablesBMJ, 2006
- Efficacy of antidepressants in adultsBMJ, 2005
- On the practice of dichotomization of quantitative variables.Psychological Methods, 2002
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960